SZ0232 is a small molecule mPGES-2 (microsomal prostaglandin E synthase-2) inhibitor with IC50 of <1 uM, exhibits beneficial effects on modulating β-cell function and glucose metabolism both in vitro and in vivo.

MPO-0144 (MPO 0144) is a potent, selective mPGES-1 inhibitor (PGE2 IC50=41.77 nM, mPGES-1 IC50=1.16 nM), exhibits potent neuroprotection (ED50=3.0 nM) against 6-OHDA-induced in PC12 cells without significant neurotoxicity (IC50>10 uM).

LY3023703 is a potent, highly selective microsomal prostaglandin E synthase 1 (mPGES1) inhibitor, dose-dependently inhibits PGE2 production in human whole blood ex vivo.

YPD-29B is a potent, specific programmed cell death ligand 1 (PD-L1) inhibitor, effectively blocks the binding of PD-1 and PD-L1 with IC50 of 0.08 pM in HTRF protein-protein interaction assays.

MAX10181 (MAX-10181) is an orally active small molecule PD-L1 inhibitor, shows similar efficacy as Durvalumab in the head to head test of human PD-L1 knock-in MC38 cell line in human PD-1 knock-in mice.

IMMH-010 maleate (YPD-30) is an ester prodrug of YPD-29B, a high potent PD-L1 inhibitor (IC50=0.08 pM), YPD-30 is a potent PD-L1 inhibitor with IC50 of 45.2 nM in HTRF assays.

IMMH-010 (YPD-30) is an ester prodrug of YPD-29B, a high potent PD-L1 inhibitor (IC50=0.08 pM), YPD-30 is a potent PD-L1 inhibitor with IC50 of 45.2 nM in HTRF assays.

BMS136 is a small molecule h-PD1/h-PD-L1 interaction inhibitor with IC50 of 96.7 nM, bind specifically to hPD-L1 through a unique mode of action, induces the dimerization of hPD-L1.

BMS135 is a small molecule h-PD1/h-PD-L1 interaction inhibitor with IC50 of 79.1 nM, bind specifically to hPD-L1 through a unique mode of action, induces the dimerization of hPD-L1.

ZYIL1 is an oral small molecule NLRP3 inflammasome inhibitor, exhibits potent (IC50 in nanomolar range) in human whole blood and supresses inflammation caused by the NLRP3 inflammasome.

NP3-146 is a small molecule NLRP3 inflammasome inhibitor and an analog of MCC950.

NLRP3-inhibitory compound 7 (NIC7) is a small-molecule inhibitor of Nod-like receptor family pyrin domain-containing 3 (NLRP3), inhibits NLRP3-mediated activation of caspase 1 along with the secretion of IL-1β, IL-18, and lactate dehydrogenase.

NDT-19795 is the carboxylic acid metabolite of selective NLRP3 inhibitor NT-0796, suppresses release of IL-1β in LPS-activated human PBMCs with IC50 of 47 nM.

ML146 (ML-146, Pubmed CID-1088438) is a selective small molecule NOD1 inhibitor with IC50 of 1.5 uM in NOD1 agonist-stimulated NF-κB reporter assay in HEK293T cells.

JT002 is a potent and selective inhibitor of NLRP3 inflammasome with IC50 of 6 nM (IL-1β production from hPBMCs), inhibits NLRP3 mediated cytokine production and pyroptosis.

JT001 (JT-001) is a potent, highly specific NLRP3 inhibitor, inhibits NLRP3 inflammasome assembly.

JC2-11 is an anti-inflammasome compound and a pan-inhibitor of the NLRP3, NLRC4, and AIM2 inflammasomes.

FK565 is an immunoactive peptide and a nucleotide-binding oligomerization domain (Nod)-1 ligand agonist.

FK156 is an immunoactive peptide and a nucleotide-binding oligomerization domain (Nod)-1 ligand agonist.

ADS032 (ADS-032) is the first, reversible and stable dual NLRP1 and NLRP3 inflammasome inhibitor, inhibits nigericin-induced NLRP3-induced IL-1β secretion from LPS-primed iBMDMs with IC50 of 30 uM.

T1059 is a selective inhibitor of eNOS/iNOS with a long-term vasoconstrictive effect in vivo.

PCC-0105002 is a novel small molecule inhibitor of PSD95-nNOS protein-protein interaction with IC50 of 1.4 uM.

TJ-M2010-2 is a small molecule inhibitor of MyD88 homodimerization, interacts with MyD88 TIR domain.

KME-3859 is a potent, selective IRAK4 inhibitor with IC50 of 5 nM, 100-fold selective over IRAK1.

KME-2780 (KME2780) is a potent and selective dual IRAK1 and IRAK4 (IRAK1/4) inhibitor with IC50 of 19 and 0.5 nM, respectively.

Rytvela (Peptide 101.10) is a potent, selective, allosteric negative modulator (antagonist) of IL-1 receptor I (IL-1RI), inhibits dose-dependently IL-1-induced PGE2 formation (IC50= 0.5 nM) and IL-1-induced human thymocyte (TF-1 cell) proliferation (IC50=

MK-886 (L-663,536) is a potent, selective and orally active inhibitor of 5-lipoxygenase-activating protein (FLAP) with IC50 of 30 nM.

Peptide WWGKKYRASKLGLAR is a super agonist of complement factor C3aR, 12-15 times more active than natural C3a.

T-ALZ01 (CMP-1696) is a small molecule inhibitor of complement component C1r.

DF3016A (DF 3016A) is a potent and selective C5aR inhibitor with IC50 of 50 nM (C5a-induced human PMN migration and IC50 of 45 and 37 nM against rat and mouse C5aR, respectively.